Name : Canine TEM1/CD248 Protein
Product Source :
Recombinant Canine TEM1/CD248 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Gln18-Gly687.[Accession | XP_025302002.1]
Molecular Weight :
The protein has a predicted MW of 72.72 kDa. Due to glycosylation, the protein migrates to 120-140 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Canine TEM1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Canine TEM1 is greater than 95% as determined by SEC-HPLC.
Background :
Colorectal cancer (CRC) is one of the most common cancers worldwide usually diagnosed in the advanced stage. The serum concentration of tumor endothelial marker 1 (TEM1) was measured and correlated with clinicopathological features to evaluate whether TEM1 might serve as a biomarker for early CRC diagnosis, progression, and prognosis. TEM1 can act as a potential diagnostic, progression, and prognostic serum biomarker for patients with CRC; TEM1 might be a good supplement for commonly used markers CEA and Ca 19-9.
Synonyms :
Endosialin; CD248; CD164L1; TEM1; CD164 sialomucin-like 1; CD164L1; CD248 molecule
References & Citations :
(1) Pietrzyk Ł, Wdowiak P. Endosialin (TEM1) as a Diagnostic, Progression, and Prognostic Serum Marker for Patients With Colorectal Cancer-A Preliminary Study. Cancer Control. 2020 Jan-Dec;27(1):1073274820903351. doi: 10.1177/1073274820903351. PMID: 32107922; PMCID: PMC7053787.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
MCP-1/CCL2 ProteinSource
TNFRSF14 ProteinPurity & Documentation
Popular categories:
Inhibin B
IFN-ω